Covid-19 roundup: No­var­tis treat­ment comes up short in PhI­II; Hu­mani­gen ex­pands tri­al, but draws crit­i­cism

A ma­jor play­er try­ing to adapt an an­ti-in­flam­ma­to­ry for Covid-19 has seen the drug fall flat.

No­var­tis re­port­ed Fri­day that a Phase III tri­al eval­u­at­ing canakinum­ab in hos­pi­tal­ized Covid-19 cas­es with pneu­mo­nia and cy­tokine re­lease syn­drome did not meet its pri­ma­ry end­point. The in­ter­im analy­sis showed that the drug did not im­prove the chance of sur­vival with­out the need for ven­ti­la­tors com­pared to the con­trol group.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.